September 2026 Research Update

Together, these papers suggest that genetic testing can often identify an inherited cause in people evaluated for Marfan syndrome or related inherited aortic conditions, but results can also be uncertain (variants of unknown meaning). When a clear disease-causing variant is found, testing and heart blood vessel imaging in relatives can identify additional family members at risk, sometimes before a major emergency happens. Evidence here comes from one family-based genetic report and two retrospective studies, one of them explicitly at a single center, so results may differ by clinic and referral patterns. [1] [2] [3]

In one cardiothoracic surgery cohort of 139 people tested for suspected hereditary thoracic aortic disease, about one in four had a pathogenic or likely pathogenic variant, while about one in five had a variant of uncertain significance. Family follow-up included 87 relatives who were screened; 18 relatives underwent preventive aortic surgery, and five family members had serious aortic events (three deaths and two dissections), showing that inherited risk can affect multiple relatives and may be recognized only after an event. [2]

In a marfanoid-habitus referral group (51 people tested with a custom multigene panel), variants were reported in 28 people, for an overall diagnostic yield of 54.9%. People with FBN1 variants (a common Marfan-related gene) had higher systemic scores than people with variants in other genes, and the score helped discriminate FBN1-related cases in this dataset. Exome sequencing in panel-negative cases found additional variants across several genes, suggesting that broader testing may sometimes add information when a targeted panel is unrevealing. [3]

A detailed report of a single Chinese family used whole-exome sequencing to identify a novel FBN1 variant that tracked with Marfan syndrome in the family and was linked to reduced fibrillin-1 signal in aortic tissue, supporting its likely role in disease. The same report described one person carrying three separate pathogenic variants linked to Marfan syndrome, familial high cholesterol, and a muscle condition, illustrating that more than one inherited condition can exist in the same individual and complicate the overall health picture. This is one-family evidence and may not reflect how often these combinations occur. [1]

For patients and caregivers, these studies mainly add context about what genetic testing and family screening can and cannot answer right now: a genetic cause is found in a meaningful portion of evaluated patients, but uncertain results are also common and may not clearly explain risk on their own. The work also shows how identifying a familial variant can guide which relatives are offered targeted testing and aortic imaging, sometimes leading to preventive surgery in relatives. What remains uncertain is how these percentages apply to different populations, and how best to interpret variants of uncertain significance over time. [2] [3] [1]

Across these studies, Marfan-related aortic disease was described as a mix of cell behavior changes (in smooth muscle and the inner lining of the vessel) and structural changes in the vessel wall (microfibrils and collagen) that together affect how the aorta handles mechanical stress. The biomarker signals were mostly measured in aortic tissue or cells rather than in routine blood tests, so they currently fit best as research tools. Overall evidence is exploratory to moderate, with several studies limited by small sample sizes and model-specific constraints. [4] [5] [6] [7] [8]

In human thoracic aortic aneurysm tissue, levels of the RNA-editing enzymes ADAR1 and ADAR2 were higher in Marfan syndrome samples than in other aneurysm groups, and ADAR2 levels in smooth muscle cells tracked with larger ascending aorta size. In Marfan-derived smooth muscle cells, many RNA editing sites were less edited than expected, suggesting that shifts in RNA editing may reflect (or contribute to) how severely the aorta is affected. [4]

At the nanoscale level in human aortic tissue, fibrillin-1 microfibrils from Marfan syndrome showed more irregular structure and lower stiffness than microfibrils from non-Marfan controls, which could reduce the wall's load-bearing capacity. The reduction in mechanical stiffness was strongest in the group with haploinsufficient FBN1 variants compared with dominant-negative variants, pointing to genotype-linked differences in microfibril strength. [5]

In Marfan mouse aortas, the vessel wall behaved as stiffer and more viscous than wild-type tissue, while collagen looked more disorganized at rest and then aligned more strongly when stretched. In living mice, pulse wave velocity (a measure related to stiffness) was higher early and then dropped later as the aorta enlarged, and some vascular mechanics differed by sex. [8]

Two studies focused on how smooth muscle and endothelial (vessel-lining) cells may change state in Marfan syndrome. Single-cell protein profiling in a Marfan mouse model identified multiple smooth muscle cell subtypes and signs consistent with endothelial-to-mesenchymal transition, with genotype- and sex-related shifts in cell populations and protein markers. Separately, human Marfan smooth muscle cells showed higher TRPV4 (and TRPM5), and TRPV4 levels influenced cell growth, wound closure behavior, and inflammatory signaling in lab experiments, suggesting TRPV4 as a mechanosensitive candidate linked to remodeling. [6] [7]

For patients and caregivers, these papers mainly add background on why the Marfan aorta can change over time: the wall's building blocks (fibrillin microfibrils and collagen) and the behavior of vessel cells both appear altered, and researchers are mapping measurable tissue signals (such as ADAR1/ADAR2 and TRPV4) that might one day help classify disease activity or severity. For now, the reported markers are not presented as standard clinical tests, and several results come from small human tissue series or Marfan mouse models, so it remains uncertain which signals will best translate into routine monitoring or risk prediction in people.

Across these papers, outcomes after complex aortic surgery in Marfan syndrome and related connective tissue conditions looked generally durable, with low early death rates in a mid-sized single-center group and stable long-term graft performance. At the same time, the reports highlighted that important complications can occur, including later aneurysms at surgical patch sites and, more rarely, severe bleeding events that may happen months after surgery. [9] [10]

In a retrospective study of 56 people with connective tissue disease (mostly Marfan syndrome) who had open thoracoabdominal aortic repair, 30-day death was 2% and 1-year death was 5%. Some serious complications were uncommon but present, including spinal cord injury with temporary leg weakness in 2% and kidney failure needing dialysis at discharge in 4%. [9]

Longer-term follow-up in the same cohort suggested reconstructed branch vessels stayed open at high rates (for example, 98% for the celiac artery and 100% for the superior mesenteric and left kidney arteries). A notable later complication was intercostal patch aneurysm in 15%, and more than half of these needed an additional minimally invasive repair. [9]

A separate single-patient report described a 40-year-old woman with Marfan syndrome who developed a very large chest cavity bleed months after thoracic aortic surgery while taking warfarin. Bleeding control was achieved using artery-blocking treatment (embolization) even though the exact bleeding point was not clearly seen on angiography, and later imaging showed the collection shrank and eventually resolved after blood thinning was restarted. [10]

For patients and caregivers, these studies add context about what can happen after major aortic surgery in Marfan syndrome: in one experienced center, early survival was high and repaired vessels stayed open for years, but some complications can appear later and may require additional procedures. The case report suggests that, in at least one situation, a serious delayed bleeding complication after surgery and blood thinners was managed without repeat open surgery, but this is based on one person and may not apply broadly. Overall, the evidence here mainly helps with understanding potential longer-term monitoring needs and the range of complications reported, rather than changing care on its own.

Across these reports, aortic emergencies and high-risk aortic aneurysms in pregnancy were managed with major heart and aorta surgery, sometimes coordinated with cesarean delivery. Maternal survival was generally high in these small, single-center experiences, but fetal loss and newborn complications still occurred, showing that fetal risk can remain substantial even when the mother survives. [11] [12] [13]

In an 8-patient case series of pregnant people undergoing aortic surgery (most often open surgery in the second trimester for an enlarged aortic root, often linked to Marfan syndrome), there were no maternal deaths. Six pregnancies resulted in live births, and two ended in intrauterine fetal demise, highlighting that fetal outcomes may be less predictable than maternal outcomes in this setting. [11]

In a 12-patient retrospective series of acute type A aortic dissection during pregnancy treated with emergency repair, 2 mothers died in the hospital and 4 pregnancies ended in fetal death (including one due to fetal malformation and three after pregnancy termination when the fetus was not viable). Among the mothers and newborns who survived to discharge, the report described good health at 1 year, although one survivor later needed an additional aortic procedure for a separate downstream problem. [12]

A case report described one 41-year-old pregnant woman with Marfan syndrome and an enlarged ascending aorta who developed an acute type A dissection at 27 weeks. She had an emergency cesarean delivery followed by complex aortic surgery (including arch repair and valve replacement), and both mother and newborn survived after a long hospital stay and postoperative rhythm problems. [13]

For patients and caregivers, this set of papers mainly provides real-world context about how life-threatening aortic problems in pregnancy have been handled in specialized hospitals, including situations affecting people with Marfan syndrome. The evidence is limited because the studies were small, single-center, and mostly descriptive, so they cannot predict what will happen for any one person. The overall picture suggests maternal survival can be achievable even with very major surgery, while fetal and newborn outcomes can vary widely depending on factors like urgency and pregnancy stage, and important uncertainties remain about outcomes across different hospitals and patient groups. [11] [12] [13]

This months papers point to measurable eye differences in Marfan syndrome that relate to the type and location of FBN1 gene variants, and to micro-structure differences seen on high-resolution corneal imaging. Separately, a single case report highlights that serious infection can occur after intraocular lens surgery, including delayed onset, and may require repeated procedures. [14] [15] [16]

In a two-stage discovery and validation study of 490 people with Marfan syndrome and ectopia lentis (a shifted eye lens), haploinsufficient FBN1 variants were linked to higher axial length (a longer front-to-back eye measurement) than dominant-negative variants. A combined genotype score (based on mutation type and location) tracked with longer axial length, and higher scores were also linked to thinner central corneal thickness, while the severity of ectopia lentis did not match genotype patterns. [14]

In a cross-sectional case-control study using in vivo confocal microscopy, 30 people with genetically confirmed FBN1-related Marfan syndrome had lower values on several corneal nerve measurements than 19 healthy controls. The study also described qualitative nerve changes such as simplified branching and microneuroma-like enlargements, while one nerve width measure was similar between groups. [15]

One case report described a 7-year-old boy with Marfan syndrome who developed delayed-onset endophthalmitis (a serious eye infection) due to Staphylococcus warneri after a scleral-sutured intraocular lens implant. The infection recurred and required multiple surgeries including vitrectomy and removal of the lens implant and sutures, followed later by re-implantation; vision improved to 20/40 with no recurrence at 6 months. Because this report involves one child, it cannot show how often this happens or who is most at risk. [16]

For patients and caregivers, these studies add context about what eye doctors may measure or notice in Marfan syndrome: some eye size and corneal thickness differences may relate to the specific FBN1 variant group, while corneal nerve changes can be seen with specialized corneal imaging. The surgical infection report is mainly a reminder that rare but serious complications can occur after lens implant surgery, including delayed infection, but one case cannot estimate typical risk. It remains uncertain how genotype-linked measurements or corneal nerve imaging results should be used to predict future eye problems in day-to-day care. [14] [15] [16]

Across two single-patient reports, doctors described heart problems in Marfan syndrome that were not straightforward based on standard testing. One report showed a mitral valve change that looked like an infection-related growth on ultrasound but turned out to be a noninfectious Marfan-related change, while the other showed a dangerous heart rhythm event in a person without major valve disease or weak heart pumping.

In a 7-year-old girl hospitalized for pneumonia, an ultrasound of the heart showed a vegetation-like structure on the mitral valve along with mitral valve prolapse and moderate leakage, raising concern for infective endocarditis (a heart valve infection). Blood cultures stayed negative and the valve finding did not go away after antibiotics; earlier images suggested the lesion had been present for about a year. Genetic testing found an FBN1 gene variant consistent with Marfan syndrome, and the lesion was ultimately labeled myxoma-like (myxomatous) valve degeneration rather than infection. [17]

In a 22-year-old man with Marfan syndrome, ventricular fibrillation (a life-threatening heart rhythm) occurred despite preserved left ventricular function and only mild aortic valve leakage with mild-to-moderate mitral valve leakage. His electrocardiogram showed a longer-than-usual QT interval, and broader genetic testing did not find an additional clear rhythm disorder gene beyond the known FBN1 variant. He received a subcutaneous implantable cardioverter-defibrillator, and the authors emphasized that serious rhythm problems may occur even when routine heart function tests look relatively reassuring. [18]

For patients and caregivers, these reports mainly provide background context: some Marfan-related valve changes can mimic infection on an ultrasound scan, and rare but serious rhythm events can still happen even without severe valve disease or weak heart pumping. Because both papers describe single individuals and not larger groups, they cannot tell how common these situations are or who is most at risk. The uncertainty that remains is how best to separate infection from noninfectious valve changes using routine tests alone, and which features (if any) reliably identify Marfan patients at higher risk for dangerous rhythms.

A single case report highlighted that unusual artery shape changes seen in Marfan syndrome (twisting and widened areas) may play a role in forming a clot in the carotid artery, and that the best way to treat this kind of clot is still uncertain. [19]

In this report, one patient with Marfan syndrome developed a free-floating clot in the carotid artery while on long-term warfarin. The clot was effectively managed after treatment with enoxaparin, but the authors emphasized that this is one-person experience and not a settled standard approach. [19]

The authors discussed a practical dilemma: when a clot happens even while someone is already taking an anticoagulant, it is not clear which medication strategy is most appropriate for future patients with similar artery changes. They called for further research to clarify optimal treatment strategies. [19]

For patients and caregivers, this report mainly serves as background information showing that blood clots in large neck arteries can occur in Marfan syndrome, possibly related to the underlying artery structure, and that clinicians may face uncertainty when selecting anticoagulation if a clot occurs despite long-term therapy. Because it describes only one person, it cannot predict what will happen for others or establish which anticoagulant is best, and larger studies are still needed. [19]